vericel
host
virtual
analyst
investor
day
october
cambridge
globe
newswire
vericel
corporation
nasdaq
vcel
leader
advanced
therapies
sports
medicine
severe
burn
care
markets
host
virtual
analyst
investor
day
friday
october
et
event
vericel
executives
provide
general
business
update
well
current
commercialization
plans
concentrate
proteolytic
enzymes
enriched
bromelain
additionally
burn
surgeon
thought
leaders
discuss
current
burn
debridement
practices
nexobrid
upon
approval
food
drug
administration
fda
could
change
current
treatment
paradigm
debridement
severe
thermal
burns
presentation
live
webcast
http
available
listen
live
broadcast
replay
archived
available
http
vericel
corporation
vericel
leader
advanced
therapies
sports
medicine
severe
burn
care
markets
company
markets
two
cell
therapy
products
united
states
autologous
cultured
chondrocytes
porcine
collagen
membrane
autologous
cellularized
scaffold
product
indicated
repair
symptomatic
single
multiple
cartilage
defects
knee
without
bone
involvement
adults
cultured
epidermal
autografts
permanent
skin
replacement
treatment
patients
deep
dermal
burns
greater
equal
total
body
surface
area
company
also
holds
exclusive
license
north
american
commercial
rights
nexobrid
biological
orphan
product
debridement
severe
thermal
burns
september
vericel
announced
fda
accepted
biologics
license
application
bla
seeking
approval
nexobrid
eschar
removal
debridement
adults
deep
thermal
burns
fda
assigned
prescription
drug
user
fee
act
pdufa
target
date
june
information
please
visit
company
website
registered
trademarks
vericel
corporation
registered
trademark
mediwound
used
license
vericel
corporation
vericel
corporation
rights
reserved
investor
contacts
lee
stern
solebury
trout
lstern
